Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 25, 2018

View Archived Issues

Repurposed antifungal may be therapy for rare blood disorder

New rat model of glutaric aciduria type I confirms cerebral ammonium accumulation

Phase I trial explores AMG-510 for solid tumors with KRAS p.G12C mutation

TREM-1 activation may alleviate development of neonatal bronchopulmonary dysplasia

Panic-prone states facilitate fear by reducing mGlu2 function within the amygdala network

Inhibitors of stromal p38MAPK/MK2 limit breast cancer metastasis and prevent bone loss

Gene therapy for cocaine addiction

Skeletal stem cell identified

AAV-mediated gene transfer of scFvs shows viability for treatment of methamphetamine abuse in mice

Thiomannosides, new oral FimH inhibitors for the treatment of urinary tract infections

ASTRID study of enobosarm does not achieve statistical significance on the primary endpoint

Eybelis granted marketing approval for glaucoma and ocular hypertension in Japan

Beova granted marketing approval in Japan for overactive bladder

Xospata approved in Japan for FLT3 mutation-positive relapsed or refractory AML

PhaseBio reports promising phase I results with ticagrelor reversal agent PB-2452

FDA lifts clinical hold for Sarepta's DMD micro-dystrophin gene therapy program

Ovid initiates phase II studies of OV-935 for rare epilepsies

AnaptysBio reports promising topline proof-of-concept data on etokimab in severe eosinophilic asthma

New PKU mouse model developed

FDA lifts partial clinical hold on tazemetostat trials

Imfinzi approved in E.U. for locally advanced, unresectable NSCLC

Phase IIa trial of EPI-589 in ALS shows improvement in CSF and plasma-based biomarkers

FDA grants approval for Copiktra for CLL/SLL, accelerated approval in follicular lymphoma

Japanese approval for Jivi for hemophilia A

Pharmaxis synthesizes new LOX inhibitors

First patient enrolled in phase I study of THR-687 for the treatment of diabetic macular edema

Phase III trial of Soliris in neuromyelitis optica spectrum disorder meets primary endpoint

Japanese approval for Blincyto for relapsed or refractory B-cell ALL

Statistically significant reduction in abdominal pain seen in phase IIa study of olorinab

Catabasis initiates phase III trial of edasalonexent for Duchenne muscular dystrophy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...